Current Antithrombotic Treatments for Cardiovascular Diseases : A Comprehensive Review
(2024) In Reviews in Cardiovascular Medicine 25(8).- Abstract
Antithrombotic therapies (ATT) play a pivotal role in the management of cardiovascular diseases, aiming to prevent ischemic events while maintaining a delicate balance with the patient’s bleeding risk. Typically, ATT can be classified into antiplatelet and anticoagulant therapies. Their application spans a broad spectrum of cardiovascular conditions, ranging from ischemic heart disease to atrial fibrillation, encompassing venous thromboembolisms and innovative structural interventional cardiology procedures. The global burden of cardiovascular diseases is steadily increasing, often giving rise to overlapping clinical presentations. Accordingly, the adoption of combined pharmacological approaches becomes imperative, potentially... (More)
Antithrombotic therapies (ATT) play a pivotal role in the management of cardiovascular diseases, aiming to prevent ischemic events while maintaining a delicate balance with the patient’s bleeding risk. Typically, ATT can be classified into antiplatelet and anticoagulant therapies. Their application spans a broad spectrum of cardiovascular conditions, ranging from ischemic heart disease to atrial fibrillation, encompassing venous thromboembolisms and innovative structural interventional cardiology procedures. The global burden of cardiovascular diseases is steadily increasing, often giving rise to overlapping clinical presentations. Accordingly, the adoption of combined pharmacological approaches becomes imperative, potentially disrupting the delicate equilibrium between ischemic and bleeding risk, thus leading to nuanced pharmacotherapeutic pathways. In this context, contemporary investigations strive to identify a convergence point that optimizes the duration of medical therapy while addressing the need for antithrombotic effects, especially in the context of ischemic heart disease. This review aims to comprehensively revisit the main antithrombotic strategies in cardiovascular diseases, with the intention of enhancing a systematic approach which is key for the effective clinical management of these patients. Also, the review will examine the most impactful studies that have established the groundwork for current scientific evidence, with acknowledgement of special populations. Finally, we will cast a gaze into the future of this dynamic and evolving research field, exploring forthcoming perspectives and advancements.
(Less)
- author
- organization
- publishing date
- 2024-08
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- anticoagulation therapy;, antiplatelet therapy;, antithrombotic treatments;, bleeding risk;, cardiovascular diseases, ischemic risk;, risk-to-benefit ratio;
- in
- Reviews in Cardiovascular Medicine
- volume
- 25
- issue
- 8
- article number
- 281
- publisher
- IMR Press Limited
- external identifiers
-
- pmid:39228474
- scopus:85201706839
- ISSN
- 1530-6550
- DOI
- 10.31083/j.rcm2508281
- language
- English
- LU publication?
- yes
- id
- 275c8a58-a862-4406-89f5-774a232a9026
- date added to LUP
- 2024-10-30 10:29:21
- date last changed
- 2025-07-10 21:53:34
@article{275c8a58-a862-4406-89f5-774a232a9026,
abstract = {{<p>Antithrombotic therapies (ATT) play a pivotal role in the management of cardiovascular diseases, aiming to prevent ischemic events while maintaining a delicate balance with the patient’s bleeding risk. Typically, ATT can be classified into antiplatelet and anticoagulant therapies. Their application spans a broad spectrum of cardiovascular conditions, ranging from ischemic heart disease to atrial fibrillation, encompassing venous thromboembolisms and innovative structural interventional cardiology procedures. The global burden of cardiovascular diseases is steadily increasing, often giving rise to overlapping clinical presentations. Accordingly, the adoption of combined pharmacological approaches becomes imperative, potentially disrupting the delicate equilibrium between ischemic and bleeding risk, thus leading to nuanced pharmacotherapeutic pathways. In this context, contemporary investigations strive to identify a convergence point that optimizes the duration of medical therapy while addressing the need for antithrombotic effects, especially in the context of ischemic heart disease. This review aims to comprehensively revisit the main antithrombotic strategies in cardiovascular diseases, with the intention of enhancing a systematic approach which is key for the effective clinical management of these patients. Also, the review will examine the most impactful studies that have established the groundwork for current scientific evidence, with acknowledgement of special populations. Finally, we will cast a gaze into the future of this dynamic and evolving research field, exploring forthcoming perspectives and advancements.</p>}},
author = {{Galanti, Kristian and Marino, Mario Di and Mansour, Davide and Testa, Sabrina and Rossi, Davide and Scollo, Claudio and Magnano, Roberta and Pezzi, Laura and D’Alleva, Alberto and Forlani, Daniele and Vitulli, Piergiusto and Paloscia, Leonardo and Ricci, Fabrizio and Renda, Giulia and Gallina, Sabina and Marco, Massimo Di}},
issn = {{1530-6550}},
keywords = {{anticoagulation therapy;; antiplatelet therapy;; antithrombotic treatments;; bleeding risk;; cardiovascular diseases; ischemic risk;; risk-to-benefit ratio;}},
language = {{eng}},
number = {{8}},
publisher = {{IMR Press Limited}},
series = {{Reviews in Cardiovascular Medicine}},
title = {{Current Antithrombotic Treatments for Cardiovascular Diseases : A Comprehensive Review}},
url = {{http://dx.doi.org/10.31083/j.rcm2508281}},
doi = {{10.31083/j.rcm2508281}},
volume = {{25}},
year = {{2024}},
}